Article and Video CATEGORIES

Cancer Journey

Search By

Karen Reckamp, MD, MS, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center (COHCCC). She received her medical degree from University of Chicago, and her master’s degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital and a Hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.

Lung Cancer Video Library - Immunotherapy for Previously Treated Patients with NSCLC
Thu, 03/08/2018 - 12:26
Karen Reckamp, MD, MS, GRACE Faculty



Immunotherapy for Previously Treated Patients with Non-Small Cell Lung Cancer (NSCLC) Presented by Karen Reckamp, MD, MS Co-Director, Lung Cancer and Thoracic Oncology Program Medical Director, Clinical Research Operations City of Hope Comprehensive Cancer Center Duarte, California


I’m Karen Reckamp, I’m a medical director for Thoracic Oncology and the medical director for Clinical Research at the City of Hope Comprehensive Cancer Center in Duarte, California. The role of immunotherapy as second-line therapy for non-small cell lung cancer has been established. Most patients who do not receive immunotherapy, essentially checkpoint inhibition PD1 or PDL1 inhibition, as first-line therapy are eligible to receive it as second-line therapy after the standard first therapy. The immunotherapy has shown to improve overall survival for patients over the previous standard of care Docetaxel. Most patients at this point receive immunotherapy being anti-PD1 or anti-PDL1 immunotherapy as second-line therapy. The role of Docetaxel and Ramucirumab has thus shifted as in the initial trial these drugs were used in the setting post first-line chemotherapy. Generally, these drugs are used after immunotherapy as the second systemic cytotoxic therapy. For patients who are not able to tolerate immunotherapy or patients who have active auto-immune phenomenon, the combination of Ramucirumab and Docetaxel is an option and again does provide improved overall survival, improved progression-free survival, and increases tumor shrinkage over Docetaxel alone in patients with non-small cell lung cancer.

 We would like to thank the following companies for their support of this program











Video Language

Next Previous link

Previous PostNext Post

Related Content

Community Forum

Hi CDaniele,
Welcome to Grace. If the TKI is working except for one or 2 places local treatment such as radiation can be used to get rid of the resistant cells...

I forgot to tell you that Grace is having its annual OncTalk live forum online Saturday, Dec. 11 at 8 am Pacific and 11 am Eastern
It will be invaluable to...

This is indeed a happy Thanksgiving in our house. I'll post about it at soon but we've just come out of a dark place and are feeling so hopeful today.

Hi and welcome to Grace.  I'm sorry your sister-in-law is going through this it's so unsettling, to say the least.  Cancer travels through the lymph system but also through blood vessels. ...

Hi Tronique,  I can't say if you do or don't have a pancoast tumor but it sounds like there are a dozen other reasons you're having your symptoms and several reasons...

Recent Comments

By JanineT Forum … on Wed, 12/01/2021 - 10:24
2021 OncTalk Dec. 11 Free Online with Expert Faculty
By JanineT Forum … on Sat, 11/27/2021 - 13:49
By JanineT Forum … on Fri, 11/26/2021 - 12:28
Happy Thanksgiving
By JanineT Forum … on Wed, 11/24/2021 - 12:38